Sökning: onr:"swepub:oai:gup.ub.gu.se/257849" >
Characteristics of ...
-
Grenabo, Lars,1949Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology
(författare)
Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
-
2017-08-29
-
Informa UK Limited,2017
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/257849
-
https://gup.ub.gu.se/publication/257849URI
-
https://doi.org/10.1080/03007995.2017.1361914DOI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Objective: To assess the characteristics of tolterodine extended-release (ER) 4mg responders and suboptimal responders (<= 50% decrease in UUI episodes/24 h) among patients with overactive bladder (OAB), including urgency urinary incontinence (UUI), and identify predictors of a >50% UUI response with fesoterodine 8mg in tolterodine suboptimal responders. Methods: Adult patients with OAB symptoms for >= 6 months and >= 8 micturitions, and >= 2 and <15 UUI episodes/24 h at week -2 received open-label tolterodine ER 4mg during a 2 week run-in. Suboptimal responders after tolterodine treatment (week 0) were randomized to fesoterodine (4mg for 1 week, 8mg for weeks 2-12) or placebo once daily. Post-hoc analyses compared the percentage change from week -2 to week 0 in UUI episodes/24 h in tolterodine responders versus suboptimal responders and identified significant predictors of a UUI response at week 12 with fesoterodine 8mg among tolterodine suboptimal responders. Results: Of 897 patients, 610 (68%) were UUI suboptimal responders during the run-in period. UUI episodes/24 h at week -2 were similar in tolterodine responders and suboptimal responders (4.2 vs. 4.3), but responders showed a significantly greater median percentage decrease in UUI episodes/24 h after tolterodine treatment at week 0 (80.0% versus 15.3%; p<.0001). During double-blind treatment, the percentage of patients with a UUI response at week 12 was significantly greater with fesoterodine (69.9%) than placebo (57.0%; p = .0027). Fesoterodine (vs. placebo), no previous antimuscarinic use before tolterodine run-in, and less UUI severity at baseline were significant predictors of a UUI response. Conclusions: For patients with OAB, including UUI, who were treated initially with tolterodine and showed a suboptimal UUI response, nearly 70% demonstrated a UUI response with second-line fesoterodine 8mg. No antimuscarinic use before tolterodine and fewer baseline UUI episodes were significant predictors of a UUI response with fesoterodine.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Herschorn, S.
(författare)
-
Kaplan, S. A.
(författare)
-
Cardozo, L.
(författare)
-
Scholfield, D.
(författare)
-
Arumi, D.
(författare)
-
Carlsson, M.
(författare)
-
Chapman, D.
(författare)
-
Ntanios, F.
(författare)
-
Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för urologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Current Medical Research and Opinion: Informa UK Limited33:10, s. 1731-17360300-79951473-4877
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Grenabo, Lars, 1 ...
-
Herschorn, S.
-
Kaplan, S. A.
-
Cardozo, L.
-
Scholfield, D.
-
Arumi, D.
-
visa fler...
-
Carlsson, M.
-
Chapman, D.
-
Ntanios, F.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
Current Medical ...
- Av lärosätet
-
Göteborgs universitet